(Alliance News) - Renalytix PLC on Monday said its laboratory developed test KidneyIntelX has been included in a draft guidance by Kidney Disease Improving Global Outcomes, a kidney disease-focused organisation.

The London-based kidney health-focused diagnostics company said the inclusion is for the KDIGO 2023 clinical practice guideline for the evaluation & management of chronic kidney disease. "KDIGO guideline development follows an explicit process to translate global scientific evidence review and appraisal into practical recommendations for clinicians and patients," Renalytix said.

It added: "Renalytix believes that inclusion of KidneyIntelX in the KDIGO 2023 guideline would be significant for broader adoption, clinical acceptance, and reimbursement of KidneyIntelX testing for risk assessment of patients with type 2 diabetes and early-stage kidney disease in the US and abroad."

Renalytix shares were up 2.6% to 100.00 pence each on Monday morning in London.

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.